期刊
JOURNAL OF DRUG TARGETING
卷 31, 期 7, 页码 693-699出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/1061186X.2023.2235092
关键词
Chron disease; gut dysmotility; IBD; immune system; inflammatory bowel disease; intestinal inflammation; ulcerative colitis; visceral pain; >
Inflammatory bowel diseases (IBDs) are chronic inflammatory conditions, including ulcerative colitis (UC) and Crohn's disease (CD). Pharmacological management of IBD patients is still unsatisfactory, prompting the search for novel molecular targets. Recent research suggests that P2 purinergic receptors, particularly the P2X4 receptor subtype, may be potential targets for IBD treatment. This review critically evaluates the role of the P2X4R subtype in the pathophysiology of IBDs and highlights its potential as a therapeutic target for innovative treatment strategies.
Inflammatory bowel diseases (IBDs) are a group of idiopathic, chronic, relapsing, inflammatory conditions, which include ulcerative colitis (UC) and Crohn's disease (CD). These disorders are characterised by intestinal symptoms associated with chronic inflammation of the intestinal mucosa, such as gut dysmotility and visceral pain. Currently, the pharmacological management of IBD patients is far from satisfactory in terms of efficacy and safety, thus spurring the interest of the scientific community to identify novel molecular targets for the management of these disorders. According to recent research, it appears that P2 purinergic receptors, which can regulate the host's response to inflammation, have been identified as potential targets for the treatment of IBDs. In particular, among P2 receptors, the P2X4 receptor subtype has recently captured the attention of the research community owing to its role in shaping immune/inflammatory responses. Based on this evidence, the present review has been conceived to provide a critical appraisal of the available knowledge about the role of P2X4R subtype in the pathophysiological mechanisms underlying IBDs, pointing out its potential as therapeutic target to develop innovative therapeutic strategies aimed at counteracting the inflammatory process, gut dysmotility and visceral hypersensitivity associated with these disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据